Hepatocellular Carcinoma Clinical Trial
— TACTICSOfficial title:
Phase II Study: Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib (TACTICS)
Verified date | October 2017 |
Source | Japan Liver Oncology Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety and efficacy of the combination therapy with Transcatheter Arterial Chemoembolization (TACE) and sorafenib compared to TACE alone in patients with unresectable hepatocellular carcinoma (HCC) who are not candidates for surgical resection or percutaneous ablation therapy.
Status | Active, not recruiting |
Enrollment | 228 |
Est. completion date | March 2018 |
Est. primary completion date | March 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: 1. Patients aged 20 Years or over 2. Patients who were fully informed of the study beforehand and signed the informed consent to participate in the study. 3. Patients who are expected to live more than 12 weeks. 4. Patients diagnosed with typical HCC by biopsy,cytology, or diagnostic imaging such as dynamic CT(MRI).Typical HCC is defined by AASLD criteria. 5. Patients in whom complete resection of the tumor by hepatectomy or complete tumor necrosis by local tumor necrosis therapy(RFA) cannot be expected to succeed. 6. Patients with tumors which are confirmed to the liver and can be treated by TACE(the maximum diameter equal to or less than 10cm,and the maximum number of nodule equal to or less than 10). 7. Patients with viable and measurable target lesion. 8. patients with no or one history of TACE therapy. 9. patients with an ECOG PS(Performance Status) Score of 0 or 1. 10. patients with Child-Pugh class A. 11. Patients with laboratory values that meet the following criteria: 1. Hemoglobin = 8.5 g/dl 2. Granulocytes = 1500/mm3 3. Platelet count = 50,000 /mm3 4. Total serum bilirubin = 3 mg/dl 5. AST and ALT = 6 times upper limits of normal 6. Serum creatinine = 1.5 times upper limits of normal Exclusion Criteria: 1. History of malignant tumor, excluding the following cases: 1. Curatively treated early stage cancer with a low risk of recurrence ,such as carcinoma in situ of the cervix, basal cell carcinoma, superficial bladder tumor, and early gastric cancer. 2. Malignant tumor that was curatively treated more than 3 years prior to study entry and has not recurred since then 2. Cardiac disease that meet any of the following criteria: 1. NYHA Class III or higher congestive heart failure 2. History of symptomatic coronary artery disease or myocardial infarction within 6 months before enrollment 3. Arrhythmia requiring control by antiarrhythmic drugs such as beta-blockers or digoxin 3. Serious and active infection, except for HBV and HCV 4. History of HIV infection 5. Renal dialysis 6. Diffuse tumor lesion 7. Extrahepatic metastasis 8. Vascular invasion 9. Intracranial tumor 10. Preexisting or history of hepatic encephalopathy 11. Clinically uncontrolled ascites or pleural effusion 12. Clinically severe gastrointestinal bleeding within 4 weeks of the start of treatment 13. Esophageal and/or gastric varices which has high risk of bleeding 14. History of thrombosis and/or embolism within 6 months of the start of treatment 15. History of receiving any of the following therapies: 1. Systemic chemotherapy for advanced HCC(including sorafenib therapy) 2. Local therapy, such as radiofrequency ablation, TACE, or hepatic arterial infusion within 3 months of the start of treatment 3. Current treatment with CYP3A4 inducing agents 4. Invasive surgery within 4 weeks of the start of treatment 5. History of allogenic transplantation 6. History of bone marrow transplant or haemopoietic stem cell transplant within 4 weeks of the start of this study 16. Unable to take oral medications 17. Gastrointestinal problems that may affect absorption or pharmacokinetics of the study drugs 18. Use of drugs that may affect absorption or pharmacokinetics of the study drugs 19. Concurrent disease or disability that may affect evaluation of the effects of the study drugs 20. Enrollment in another study within 4 weeks of study entry 21. Female patients who are pregnant, lactating, possibly pregnant, or planning to become pregnant 22. Risk of allergic reactions to the study drugs 23. Drug abuse or other physical, psychological , or social problems that may interfere with the participation in the study or evaluation of study results 24. Any condition that could jeopardize the safety of the patient or their compliance in the study |
Country | Name | City | State |
---|---|---|---|
Japan | Kinki University Hospital | Osaka-Sayama | Osaka |
Lead Sponsor | Collaborator |
---|---|
Japan Liver Oncology Group |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression Free Survival | Patients will be evaluated for these endpoints every 8 weeks | every 8 week | |
Primary | Overall Survival | The overall survival is defined as time from randomization to death due to any cause, and will be evaluated every 8 weeks in the protocol treatment, and every one year in the follow-up period,respectively. | every 8 week | |
Secondary | Time To Progression | Time to progression is defined as time from randomization to radiological progression and will be evaluated every 8 week. | every 8 weeks | |
Secondary | Objective Response Rate | Objective Response Rate is defined as best response | 4week after TACE | |
Secondary | Tumor markers | Change of tumor markers | every 4 weeks | |
Secondary | Safety | Number of participants with adverse events as a measure of safety and tolerability(According to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0) | every 4 weeks | |
Secondary | Time To Untreatable Progression(TTUP) | Time to untreatable progression is defined as time from randomization to untreatable progression and will be evaluated every 8 week. | every 8 week till untreatable progression, assessed up to 100 months | |
Secondary | Time to Child-Pugh C | Time to Child-Pugh C is defined as time from randomization to Child-Pugh C and will be evaluated every 8 week. | every 8 week till liver deterioration to Child-Pugh C, assessed up to 100 months | |
Secondary | Time to intrahepatic tumor progression | Time to intrahepatic tumor progression is defined as time from randomization to intrahepatic tumor progression and will be evaluated every 8 week. | every 8 week till intrahepatic tumor progression, assessed up to 100 months | |
Secondary | Time to vascular invasion | Time to vascular invasion is defined as time from randomization to vascular invasion and will be evaluated every 8 week. | every 8 week till vascular invasion, assessed up to 100 months | |
Secondary | Time to Extrahepatic spread | Time to extrahepatic spread is defined as time from randomization to extrahepatic spread and will be evaluated every 8 week. | every 8 week till extrahepatic spread, assessed up to 100 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |